Zoi Piperigkou

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2620672/publications.pdf

Version: 2024-02-01

38 papers	2,208 citations	257357 24 h-index	330025 37 g-index
45 all docs	45 docs citations	45 times ranked	2688 citing authors

#	Article	IF	Citations
1	EGFR is a pivotal player of the E2/ERÎ² â€“ mediated functional properties, aggressiveness, and stemness in tripleâ€negative breast cancer cells. FEBS Journal, 2022, 289, 1552-1574.	2.2	13
2	New Analogs of Polyamine Toxins from Spiders and Wasps: Liquid Phase Fragment Synthesis and Evaluation of Antiproliferative Activity. Molecules, 2022, 27, 447.	1.7	3
3	Tuning the Spin-Crossover Behaviour in Fe(II) Polymeric Composites for Food Packaging Applications. Magnetochemistry, 2022, 8, 16.	1.0	5
4	Hyaluronan as â€œAgent Smithâ€•in cancer extracellular matrix pathobiology: Regulatory roles in immune response, cancer progression and targeting. IUBMB Life, 2022, 74, 943-954.	1.5	3
5	The microRNA-cell surface proteoglycan axis in cancer progression. American Journal of Physiology - Cell Physiology, 2022, 322, C825-C832.	2.1	8
6	Matrix Effectors and Cancer. Cancers, 2022, 14, 200.	1.7	2
7	Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?. European Journal of Medicinal Chemistry, 2021, 210, 112948.	2.6	9
8	The action of hyaluronan in functional properties, morphology and expression of matrix effectors in mammary cancer cells depends on its molecular size. FEBS Journal, 2021, 288, 4291-4310.	2.2	11
9	Epigenetic Alterations in Triple-Negative Breast Cancerâ€”The Critical Role of Extracellular Matrix. Cancers, 2021, 13, 713.	1.7	35
10	Key Matrix Remodeling Enzymes: Functions and Targeting in Cancer. Cancers, 2021, 13, 1441.	1.7	55
11	A guide to the composition and functions of the extracellular matrix. FEBS Journal, 2021, 288, 6850-6912.	2.2	320
12	Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease. Seminars in Thrombosis and Hemostasis, 2021, 47, 295-307.	1.5	25
13	Extracellular matrix-based cancer targeting. Trends in Molecular Medicine, 2021, 27, 1000-1013.	3.5	66
14	Estrogen receptor-mediated targeting of the extracellular matrix network in cancer. Seminars in Cancer Biology, 2020, 62, 116-124.	4.3	34
15	Extracellular Matrix-Mediated Breast Cancer Cells Morphological Alterations, Invasiveness, and Microvesicles/Exosomes Release. Cells, 2020, 9, 2031.	1.8	40
16	Î•GFR/ERÎ²-Mediated Cell Morphology and Invasion Capacity Are Associated with Matrix Culture Substrates in Breast Cancer. Cells, 2020, 9, 2256.	1.8	7
17	miR-200b restrains EMT and aggressiveness and regulates matrix composition depending on ER status and signaling in mammary cancer. Matrix Biology Plus, 2020, 6-7, 100024.	1.9	21
18	Long filopodia and tunneling nanotubes define new phenotypes of breast cancer cells in 3D cultures. Matrix Biology Plus, 2020, 6-7, 100026.	1.9	29

#	Article	IF	Citations
19	Dynamic Interplay between miRNAs and the Extracellular Matrix Influences the Tumor Microenvironment. Trends in Biochemical Sciences, 2019, 44, 1076-1088.	3.7	33
20	Molecular size-dependent specificity of hyaluronan on functional properties, morphology and matrix composition of mammary cancer cells. Matrix Biology Plus, 2019, 3, 100008.	1.9	31
21	Hyaluronan: molecular sizeâ€dependent signaling and biological functions in inflammation and cancer. FEBS Journal, 2019, 286, 2883-2908.	2.2	266
22	Collagen Fiber Array of Peritumoral Stroma Influences Epithelial-to-Mesenchymal Transition and Invasive Potential of Mammary Cancer Cells. Journal of Clinical Medicine, 2019, 8, 213.	1.0	31
23	Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer. Methods in Molecular Biology, 2018, 1731, 325-348.	0.4	50
24	Insights into the key roles of epigenetics in matrix macromolecules-associated wound healing. Advanced Drug Delivery Reviews, 2018, 129, 16-36.	6.6	47
25	Proteoglycan Chemical Diversity Drives Multifunctional Cell Regulation and Therapeutics. Chemical Reviews, 2018, 118, 9152-9232.	23.0	253
26	Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer. Cellular Signalling, 2018, 51, 99-109.	1.7	38
27	Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition. Scientific Reports, 2017, 7, 45138.	1.6	59
28	Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer. Matrix Biology, 2017, 64, 94-111.	1.5	43
29	The role of heparins and nano-heparins as therapeutic tool in breast cancer. Glycoconjugate Journal, 2017, 34, 299-307.	1.4	28
30	Protein bio-corona: critical issue in immune nanotoxicology. Archives of Toxicology, 2017, 91, 1031-1048.	1.9	182
31	Shed proteoglycans in tumor stroma. Cell and Tissue Research, 2016, 365, 643-655.	1.5	70
32	Estrogen receptor beta modulates breast cancer cells functional properties, signaling and expression of matrix molecules. Matrix Biology, 2016, 56, 4-23.	1.5	66
33	Synthesis and antiproliferative activity of two diastereomeric lignan amides serving as dimeric caffeic acid-l-DOPA hybrids. Bioorganic Chemistry, 2016, 66, 132-144.	2.0	9
34	Biochemical and toxicological evaluation of nano-heparins in cell functional properties, proteasome activation and expression of key matrix molecules. Toxicology Letters, 2016, 240, 32-42.	0.4	20
35	Emerging aspects of nanotoxicology in health and disease: From agriculture and food sector to cancer therapeutics. Food and Chemical Toxicology, 2016, 91, 42-57.	1.8	107
36	Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biology, 2015, 43, 42-60.	1.5	140

#	Article	IF	Citations
37	Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulinâ€like growth factor receptor in the expression of cell surface heparan sulfate proteoglycans and cell motility in breast cancer cells. FEBS Journal, 2013, 280, 2248-2259.	2.2	47
38	ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo. Frontiers in Oncology, 0, 12, .	1.3	2